Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | GRM6 | O15303 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.54 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.54 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.54 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.54 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7095236 | 0.80 | KMT2A (0.53) | KMT2ATDP1MAPTMEN1KDM4E | |
| SCHEMBL1907253 | 0.73 | CDK2 (0.49) | KMT2ATDP1MAPTKDM4EHPGD | |
| SCHEMBL9036467 | 0.71 | KMT2A (0.53) | KMT2ATDP1MAPTMEN1KDM4E | |
| SCHEMBL8472152 | 0.71 | MAPT (0.50) | KMT2ATDP1MAPTMEN1KDM4E | |
| SCHEMBL7100168 | 0.71 | MAPT (0.67) | KMT2ATDP1MAPTMEN1KDM4E | |
| Nbqx SCHEMBL120375 | 0.70 | GRIA1 (1.00) | KMT2ATDP1MAPTMEN1KDM4E | |
| Nbqx SCHEMBL29356960 | 0.70 | GRIA1 (1.00) | KMT2ATDP1MAPTMEN1KDM4E | |
| Nbqx SCHEMBL20501770 | 0.69 | MAPT (1.00) | KMT2ATDP1MAPTMEN1KDM4E | |
| Nbqx SCHEMBL29412437 | 0.69 | MAPT (0.74) | KMT2ATDP1MAPTMEN1KDM4E | |
| Nbqx SCHEMBL2487669 | 0.69 | GRIA1 (0.98) | KMT2ATDP1MAPTMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3160464-A1 | USE OF BUSPIRONE METABOLITES | Contera Pharma APS (DK) | 2017-05-03 | — | — | EP | claimed |
| WO-2015197079-A1 | USE OF BUSPIRONE METABOLITES | CONTERA PHARMA APS (DK) | 2015-12-30 | — | — | WO | claimed |
| US-7892755-B2 | Of nitroquinoxaline-2,3-diones or ellagic acid as binding ligands for G protein coupled receptor 35; antidiabetic agents; anticarcinogenic agents for gastrointestinal cancer; obesity, immunotherapy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-22 | — | — | US | claimed |
| EP-1788390-B1 | SCREENING METHOD | TAKEDA PHARMACEUTICAL (JP) | 2010-04-14 | — | — | EP | claimed |
| US-20080103215-A1 | Screening Method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-01 | — | — | US | claimed |
| EP-1788390-A1 | SCREENING METHOD | Takeda Pharmaceutical Company Limited (JP) | 2007-05-23 | — | — | EP | claimed |
| WO-2003099282-A1 | WHITE MATTER NEUROPROTECTANT PYRROLOQUINOLINE QUINONE COMPOUNDS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2003-12-04 | — | — | WO | claimed |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | PFIZER, INC. | 2003-03-06 | — | — | US | claimed |
| US-5834465-A | FOR PROTECTING BRAIN AGAINST ACUTE DAMAGE IN STROKE, EPILEPSY, TRAUMA | WASHINGTON UNIVERSITY (US) | 1998-11-10 | — | — | US | claimed |
| US-20260021111-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | IMMEDICA PHARMA US INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12246026-B2 | Ganaxolone for use in treatment of status epilepticus | MARINUS PHARMACEUTICALS, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-20240261413-A1 | TOPIRAMATE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2024-08-08 | — | — | US | disclosed |
| EP-4395772-A1 | METHODS OF PREVENTING AND TREATING PAIN AND ASSOCIATED SYMPTOMS | Ethismos Research, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118176001-A | Methods for preventing and treating pain and related symptoms | 埃塞斯莫斯研究股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-5646132-A | TREATING CEREBRAL ISCHEMIA | ADIR ET COMPAGNIE (FR) | 1997-07-08 | — | — | US | disclosed |
| WO-1996025387-A1 | ALKYLCARBOXY AMINO ACIDS-MODULATORS OF THE KAINATE RECEPTOR | SYMPHONY PHARMACEUTICALS, INC. (US) | 1996-08-22 | — | — | WO | disclosed |
| US-5536709-A | INHIBITORS OF HYPERACTIVATION OF EXCITATORY AMINO ACIDS | ADIR ET COMPAGNIE (FR) | 1996-07-16 | — | — | US | disclosed |
| EP-0640612-A1 | Novel derivatives from 2-(1H)-quinolinone, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1995-03-01 | — | — | EP | disclosed |
| EP-0542609-A1 | 3-sulfonylamino-2-(1H)-quinolinones and 7-aza derivatives as excitatory amino acids antagonists | ADIR ET COMPAGNIE (FR) | 1993-05-19 | — | — | EP | disclosed |
| EP-0424179-A2 | Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration | Olney, John William (US) | 1991-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12246026-B2 | Ganaxolone for use in treatment of status epilepticus | CYP21A2, CYP17A1, HSD17B11 | KMT2A 2155/4885TDP1 3806/4885MAPT 2080/4885 |
| US-20240261413-A1 | TOPIRAMATE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | ADSL, SCD, PFKFB3 | KMT2A 2553/4885TDP1 2772/4885MAPT 242/4885 |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | GRIN3A, GRIN1, CHRNA10 | KMT2A 994/4885TDP1 819/4885MAPT 741/4885 |
| US-20260021111-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CYP4A11, CYP21A2, CYP17A1 | KMT2A 3151/4885TDP1 3142/4885MAPT 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.